<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448095</url>
  </required_header>
  <id_info>
    <org_study_id>CML1214</org_study_id>
    <nct_id>NCT02448095</nct_id>
  </id_info>
  <brief_title>Retrospective Evaluation of CML Patients in the National Compassionate Program</brief_title>
  <official_title>Ponatinib Survey: Retrospective Evaluation of CML Patients in the National Compassionate Program According to the 648/96 Decree</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study aims at assessing the tolerability and safety profiles of Ponatinib,
      a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is
      used during the chronic phase of the disease, according to the Italian national compassionate
      law 648/96.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observational study aims at assessing the tolerability and safety profiles of Ponatinib,
      a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is
      used during the chronic phase of the disease, according to the Italian national compassionate
      law 648/96.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Maximum of 60 months from treatment start</time_frame>
    <description>General adverse events and grade 3-4 adverse events according to NCI CTCAE version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with hematological complete response</measure>
    <time_frame>Maximum of 60 months from treatment start</time_frame>
    <description>Hematological complete response and related responses, such as major cytogenetic response, complete cytogenetic response and major molecular response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days from treatment start till response</measure>
    <time_frame>Maximum of 60 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of patients alive</measure>
    <time_frame>12 months after patient enrollment in the study</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in event free survival</measure>
    <time_frame>12 months after patient enrollment in the study</time_frame>
    <description>Event free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients in progression free survival</measure>
    <time_frame>12 months after patient enrollment in the study</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mutations</measure>
    <time_frame>Maximum of 60 months from treatment start</time_frame>
    <description>Both at the beginning and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units of Ponatinib administered per units of time</measure>
    <time_frame>Maximum of 60 months from treatment start</time_frame>
    <description>Chemotherapy dose intensity represents unit dose of chemotherapy administered per unit time.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Philadelphia Positive</condition>
  <arm_group>
    <arm_group_label>CML ph+ patients</arm_group_label>
    <description>Chronic myeloid leukemia patients who are philadelphia positive</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Observation of tolerability and safety profiles</description>
    <arm_group_label>CML ph+ patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        CML Ph+ patients in the Ponatinib compassionate use program
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CML Ph+ patients in chronic phase

          -  18 years old or older

          -  Patients have received either Dasatinib or Nilotinib and resulted resistant or not
             tolerant to the drugs or have developed the T3151 mutation

          -  Patients have started Ponatinib at least 12 months before registration

          -  Informed consent signed at registration

        Exclusion Criteria:

          -  CML Ph+ patients in accelerated or blast phase with acute lymphoblastic leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Fava</last_name>
    <role>Study Chair</role>
    <affiliation>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 - Orbassano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgina Specchia</last_name>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST.Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Gobbi</last_name>
    </contact>
    <investigator>
      <last_name>Marco Gobbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Fava</last_name>
    </contact>
    <investigator>
      <last_name>Carmen Fava</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;S.Gerardo&quot;</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Gambacorti Passerini</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Gambacorti Passerini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dip. di Scienze Cliniche e Biologiche - Ospedale S. Luigi Gonzaga-Medicina Interna 2 - Orbassano</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Fava</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ester Orlandi</last_name>
    </contact>
    <investigator>
      <last_name>Ester Orlandi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Martino</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Martino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S. Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Abruzzese</last_name>
    </contact>
    <investigator>
      <last_name>Elisabetta Abruzzese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2015</study_first_submitted>
  <study_first_submitted_qc>May 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic myeloid leukemia</keyword>
  <keyword>Philadelphia positive</keyword>
  <keyword>Compassionate use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

